LianBio
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIANY research report →
Companywww.lianbio.com
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc.
- CEO
- Adam Leo Stone
- IPO
- 2021
- Employees
- 163
- HQ
- Princeton, NJ, US
Price Chart
Valuation
- Market Cap
- $12.01M
- P/E
- 4.81
- P/S
- 0.00
- P/B
- 0.19
- EV/EBITDA
- -12.19
- Div Yield
- 390.55%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.77%
- ROIC
- -61.81%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $2.48M · -99.20%
- EPS
- $0.02 · -99.20%
- Op Income
- $-38,858,480
- FCF YoY
- -98.55%
Performance & Tape
- 52W High
- $0.44
- 52W Low
- $0.03
- 50D MA
- $0.13
- 200D MA
- $0.09
- Beta
- -0.02
- Avg Volume
- 46.53K
Get TickerSpark's AI analysis on LIANY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LIANY Coverage
We haven't published any research on LIANY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LIANY Report →